|
Conversion
|
N
|
Mean (SD) Tac-BID dose (mg/day)
|
Mean (SD) [Tac] bid (ng/ml)
|
Mean (SD) Tac-OD dose (mg/day)
|
Mean (SD) [Tac] OD (ng/ml)
|
Percentage of cohort requiring >30% increase in Tac-OD dose
|
|---|
|
Total
|
488
|
3.53 (2.01)
|
5.49 (2.36)
|
3.75 (2.03)
|
5.15 (2.48)
|
15.7
|
|
Caucasian
|
282
|
3.23 (1.94)
|
5.58 (2.34)
|
3.42 (2.14)
|
5.48 (2.93)
|
13.5
|
|
East Asian
|
91
|
3.59 (2.27)
|
5.46 (2.35)
|
4.07 (2.28)
|
4.64 (1.38)
|
27.5*
|
|
South Asian
|
75
|
3.67 (2.25)
|
5.00 (1.62)
|
3.86 (2.31)
|
4.54 (1.38)
|
8.0
|
|
African Canadian
|
18
|
6.18 (3.87)
|
5.13 (1.43)
|
6.23 (4.20)
|
5.92 (2.33)
|
11.1
|
|
Middle Eastern
|
12
|
3.04 (1.76)
|
6.39 (3.26)
|
2.96 (1.57)
|
4.70 (2.30)
|
8.3
|
|
Other
|
10
|
2.89 (2.33)
|
5.42 (2.37)
|
2.06 (2.14)
|
5.40 (2.31)
|
20.0
|
- *P = 0.03 compared to all other cohorts.
- BID, twice daily; OD, once daily; SD, standard deviation; Tac, tacrolimus.
